For its fourth fiscal quarter (ending December 31), Quest Diagnostics Inc (NYSE: DGX) has reported a 15% increase in E.P.S. from $1.72 a year ago to $1.98 in the current quarter. For the latest four quarters through December 31, E.P.S. were $7.78 compared to $7.59 a year ago — an increase of 3%.
Recent Price Action
On 1/30/25, Quest Diagnostics Inc (NYSE: DGX) stock enjoyed a very large increase of 5.6%, closing at $164.17. Moreover, exceptionally high trading volume at 297% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 8.4% during the last week.
Current PriceTarget Research Rating
Quest Diagnostics has a current Value Trend Rating of C (High Neutral). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Quest Diagnostics has a neutral Appreciation Score of 55 but a good Power Rating of 71, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment